Safety Pharmacology Department, Safety Assessment UK, AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire, UK.
Br J Pharmacol. 2010 Jan;159(1):77-92. doi: 10.1111/j.1476-5381.2009.00338.x. Epub 2009 Aug 6.
Evaluation of the potential for delayed ventricular repolarization and proarrhythmia by new drugs is essential. We investigated if dog left ventricular midmyocardial myocytes (LVMMs) that can be used as a preclinical model to assess drug effects on action potential duration (APD) and whether in these cells, short-term variability (STV) or triangulation could predict proarrhythmic potential.
Beagle LVMMs and Purkinje fibres (PFs) were used to record APs. Effects of six reference drugs were assessed on APD at 50% (APD(50)) and 90% (APD(90)) of repolarization, STV(APD), triangulation (ratio APD(90)/APD(50)) and incidence of early afterdepolarizations (EADs) at 1 and 0.5 Hz.
LVMMs provided stable recordings of AP, which were not affected by four sequential additions of dimethyl sulphoxide. Effects of dofetilide, d-sotalol, cisapride, pinacidil and diltiazem, but not of terfenadine, on APD in LVMMs were found to be comparable with those recorded in PFs. LVMMs, but not PFs, exhibited a proarrhythmic response to I(Kr) blockers. Incidence of EADs was not related to differences in AP prolongation or triangulation, but corresponded to beat-to-beat variability of repolarization, here quantified as STV of APD.
LVMMs provide a suitable preclinical model to assess the effects of new drugs on APD and also yield additional information about putative indicators of proarrhythmia that add value to an integrated QT/TdP risk assessment. Our findings support the concept that increased STV(APD) may predict drug-induced proarrhythmia.
评估新药潜在的延迟性心室复极和致心律失常作用至关重要。我们研究了是否可以将狗左心室中层心肌细胞(LVMMs)用作临床前模型来评估药物对动作电位时程(APD)的影响,以及在这些细胞中,短期变异性(STV)或三角化是否可以预测致心律失常的潜力。
使用比格犬 LVMMs 和浦肯野纤维(PFs)记录动作电位。评估了六种参考药物对复极 50%(APD(50))和 90%(APD(90))时的 APD、STV(APD)、三角化(APD(90)/APD(50)比值)以及 1Hz 和 0.5Hz 时早期后除极(EAD)发生率的影响。
LVMMs 提供了稳定的动作电位记录,四次连续加入二甲基亚砜均未对其产生影响。发现多非利特、d-索他洛尔、西沙必利、吡那地尔和地尔硫卓对 LVMMs 中的 APD 的作用与在 PFs 中记录的作用相当。LVMMs 而非 PFs 对 I(Kr)阻滞剂表现出致心律失常反应。EAD 的发生率与 AP 延长或三角化的差异无关,但与复极的逐搏变异性相对应,这里用 APD 的 STV 来量化。
LVMMs 提供了一个合适的临床前模型来评估新药对 APD 的影响,并且还提供了关于潜在致心律失常指标的额外信息,这些信息增加了对综合 QT/TdP 风险评估的价值。我们的发现支持这样的概念,即增加的 STV(APD)可能预测药物引起的致心律失常。